PETS
PetMed Express, Inc.3.9000
+1.0300+35.9%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
83.34MP/E (TTM)
-Basic EPS (TTM)
-0.30Dividend Yield
0%Recent Filings
10-Q
Q3 FY2026 results
PetMed Express posted Q3 FY2026 sales of $40.7M, down 21.7% y/y from $52.0M, with gross profit tumbling to $9.5M (23.3% margin) from $16.1M (31.0%) due to a $2.1M inventory write-down and higher promotions; operating loss hit $10.5M versus $0.5M last year, while YTD operating loss reached $53.0M after $27.3M goodwill/intangible impairments earlier. Cash burned $23.7M in operations and $3.9M on capex, leaving $26.9M on hand—no debt. Diluted EPS loss of $0.50 aligns with 21.0M shares; anti-dilution excluded others. Cash holds firm. Unsolicited buyout proposals distract management.
8-K
Shareholders approve directors, pay
PetMed Express shareholders approved all three proposals at its January 21, 2026 Annual Meeting, with 15.5M shares present forming a quorum. All five director nominees—Peter Batushansky, Leslie C.G. Campbell, James LaCamp, Justin Mennen, and Leah A. Solivan—won election despite significant opposition votes topping 3M each. Say-on-pay passed handily; Baker Tilly US, LLP ratification drew near-unanimous support. Directors serve until next meeting.
10-Q
Q1 FY2026 results
PetMed Express posted Q1 FY2026 sales of $51.2M, down 22.7% y/y from $66.2M, with gross profit at $14.4M (28.1% margin, down from 28.8%). Reorders fell 21.8% y/y to $41.3M amid prescription declines, while new orders dropped 25.6% y/y. A $27.3M goodwill and intangible impairment charge—triggered by revenue weakness and low market cap—drove a $34.2M net loss and $(1.65) diluted EPS, versus $3.8M profit and $0.18 EPS last year; anti-dilution excluded potential shares. Cash burned $12.3M in operations, leaving $41.1M on hand, no debt. Goodwill wiped out entirely. Leadership churn persists.
10-Q
Q2 FY2026 results
PetMed Express posted Q2 FY2026 net sales of $44.4M, down 23.6% y/y from $58.0M, with gross profit shrinking to $12.4M (28.0% margin vs 32.3%). Operating loss hit $8.4M amid elevated G&A at $14.2M, up 35.1% y/y from investigation fees and severance; net loss $8.5M or $(0.41) diluted EPS, anti-dilutive shares excluded. YTD sales fell 23.1% to $95.5M, operating loss $42.5M driven by $27.3M goodwill/intangible impairments (Q1). Cash drained to $36.1M after $14.4M operating outflow and $3.9M capex; no debt. Unsolicited buyout proposals distract management.
8-K
Switches auditors amid control issues
PetMed Express dismissed RSM US LLP as auditor effective after its interim reviews for quarters ended June 30 and September 30, 2025, and appointed Baker Tilly US for fiscal 2026 starting October 1, 2025, following a competitive process. No disagreements occurred, but prior material weaknesses in internal controls persist unremediated. Change won't delay Q1/Q2 10-Q filings.
IPO
Website
Employees
Sector
Industry
CHWY
Chewy, Inc.
33.34+0.20
GDRX
GoodRx Holdings, Inc.
2.76+0.05
HIMS
Hims & Hers Health, Inc.
36.86+0.61
IVP
Inspire Veterinary Partners, In
0.05-0.00
PETV
PetVivo Holdings Inc.
1.16-0.03
PMHS
Polomar Health Services, Inc.
0.08+0.00
PTPI
Petros Pharmaceuticals, Inc.
0.01-0.00
WGRX
Wellgistics Health, Inc.
0.54-0.04
WOOF
Petco Health and Wellness Compa
3.05-0.05
ZTS
Zoetis Inc.
123.23+2.25